Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
|Videos|January 3, 2014
An Analysis of the FALCON Trial
Author(s)Matthew J. Ellis, MD, PhD
Matthew J. Ellis, MD, PhD, discusses the ongoing phase III FALCON trial.
Advertisement
Matthew J. Ellis, MD, PhD, professor, Department of Medicine, Oncology Division, Breast Oncology Section, Washington University School of Medicine in St. Louis, Missouri and the Siteman Cancer Center, discusses the ongoing phase III FALCON trial.
Clinical Pearls
- The FALCON trial is comparing anastrozole to the newly approved, high-dose fulvestrant (500mg) for patients with treatment-naïve metastatic breast cancer
- The rationale of the trial is to see if the high dose of fulvestrant will maintain disease control for a longer period of time than patients receiving anastrozole
- This is a registration trial and will alter the label of fulvestrant to include treatment-naïve advanced breast cancer
Advertisement
Related to this article
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies—yet gaps persist, and research funding uncertainty threatens future gains.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
The phase 2 NRG-BR002 failed to improve outcomes with targeted radiotherapy to oligometastases; the phase 3 portion will not proceed.
ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
3
Durability of PFS and OS Benefit vs. Historical Control
4
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
5